Intercept Rumors, Alnylam’s $200M Factory, and Some Precious Ebola Antibodies

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more.

You may also like

Novavax Nabs $1.6B, BD Secures Fast Antigen Test OK, & a Tribute to Tony Fauci
Pfizer, BioNTech Vaccine Shows Life, but Cases Surge, Testing Falters & Prices Haunt
The Exponential Curves Re-Emerge
Merck Wins 2 Big Approvals, a Surprise from Old ‘Dex,’ and a Digital Therapeutics First